---
title: "Jiangsu Recbio Technology's Clinical Trial Application for HPV Vaccine Accepted in China"
date: "2025-02-13 15:32:19"
summary: "Jiangsu Recbio Technology's  application for a clinical trial of its HPV 9-valent vaccine REC604c has been accepted by China's National Medical Products Administration, a Wednesday bourse filing said. REC604c is a novel recombinant HPV 9-valent vaccine that the vaccine maker plans to develop for the male and upgraded markets."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Jiangsu Recbio Technology's application for a clinical trial of its HPV 9-valent vaccine REC604c has been accepted by China's National Medical Products Administration, a Wednesday bourse filing said.

REC604c is a novel recombinant HPV 9-valent vaccine that the vaccine maker plans to develop for the male and upgraded markets.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250213:G2467318:0/)
